EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Heterologous HSPC Transplantation Rescues Neuroinflammation and Ameliorates Peripheral Manifestations in the Mouse Model of Lysosomal Transmembrane Enzyme Deficiency, MPS IIIC

Xuefang Pan, Antoine Caillon iD, Shuxian Fan, Shaukat Khan, Shunji Tomatsu iD, Alexey V Pshezhetsky iD

Cells · 2024

DOI: 10.3390/cells13100877 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Xuefang Pan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Centre Hospitalier Universitaire Sainte-Justine Research Centre, University of Montreal, Montreal, QC H3T 1C5, Canada. Hauptthemen laut MEDLINE: Mucopolysaccharidosis III, Disease Models, Animal, Neuroinflammatory Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Glycomics Network, Sanfilippo Children's Foundation (Australia).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucopolysaccharidosis III type C (MPS IIIC) is an untreatable neuropathic lysosomal storage disease caused by a genetic deficiency of the lysosomal N-acetyltransferase, HGSNAT, catalyzing a transmembrane acetylation of heparan sulfate. HGSNAT is a transmembrane enzyme incapable of free diffusion between the cells or their cross-correction, which limits development of therapies based on enzyme replacement and gene correction. Since our previous work identified neuroinflammation as a hallmark of the CNS pathology in MPS IIIC, we tested whether it can be corrected by replacement of activated brain microglia with neuroprotective macrophages/microglia derived from a heterologous HSPC transplant. Eight-week-old MPS IIIC (HgsnatP304L) mice were transplanted with HSPC from congenic wild type mice after myeloablation with Busulfan and studied using behavior test battery, starting from the age of 6 months. At the age of ~8 months, mice were sacrificed to study pathological changes in the brain, heparan sulfate storage, and other biomarkers of the disease. We found that the treatment corrected several behavior deficits including hyperactivity and reduction in socialization, but not memory decline. It also improved several features of CNS pathology such as microastroglyosis, expression of pro-inflammatory cytokine IL-1β, and accumulation of misfolded amyloid aggregates in cortical neurons. At the periphery, the treatment delayed development of terminal urinary retention, potentially increasing longevity, and reduced blood levels of heparan sulfate. However, we did not observe correction of lysosomal storage phenotype in neurons and heparan sulfate brain levels. Together, our results demonstrate that neuroinflammation in a neurological lysosomal storage disease, caused by defects in a transmembrane enzyme, can be effectively ameliorated by replacement of microglia bearing the genetic defect with cells from a normal healthy donor. They also suggest that heterologous HSPC transplant, if used together with other methods, such as chaperone therapy or substrate reduction therapy, may constitute an effective combination therapy for MPS IIIC and other disorders with a similar etiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucopolysaccharidosis IIIDisease Models, AnimalNeuroinflammatory DiseasesAnimalsMiceLysosomesMicrogliaMice, Inbred C57BLBrainHeparan SulfateInflammation

Stichwörter der Autor:innen

HSPCSanfilippo diseaseallogenic HSPC transplantationheparan sulfatemicrogliamucopolysaccharidosisneuroinflammation

Substanzen

Heparan Sulfate

Autor:innen und Institutionen

  • Department of Pediatrics and Centre Hospitalier Universitaire Sainte-Justine Research Centre, University of Montreal, Montreal, QC H3T 1C5, Canada.
  • Department of Anatomy and Cell Biology, McGill University, Montreal, QC H3A 0C7, Canada.
  • Nemours/Alfred I. duPont Hospital for Children, Wilmington, DE 19803, USA.

ORCID-Profile: Antoine Caillon, Shunji Tomatsu, Alexey V Pshezhetsky

Förderung

  • CIHR
  • Canadian Glycomics Network
  • Sanfilippo Children's Foundation (Australia)
  • Canadian Institutes of Health Research
  • Elisa Linton Research Chair in Lysosomal Diseases
  • Cure Sanfilippo Foundation
  • Sanfilippo Children’s Foundation (Australia)
  • Fundacja Sanfilippo (Poland)

Zitieren

APA

Pan, X., Caillon, A., Fan, S., Khan, S., Tomatsu, S., & Pshezhetsky, A. V. (2024). Heterologous HSPC Transplantation Rescues Neuroinflammation and Ameliorates Peripheral Manifestations in the Mouse Model of Lysosomal Transmembrane Enzyme Deficiency, MPS IIIC. Cells. https://doi.org/10.3390/cells13100877

Vancouver

Pan X, Caillon A, Fan S, Khan S, Tomatsu S, Pshezhetsky AV. Heterologous HSPC Transplantation Rescues Neuroinflammation and Ameliorates Peripheral Manifestations in the Mouse Model of Lysosomal Transmembrane Enzyme Deficiency, MPS IIIC. Cells. 2024. doi:10.3390/cells13100877

BibTeX
@article{Pan2024,
  author = {Pan, Xuefang and Caillon, Antoine and Fan, Shuxian and Khan, Shaukat and Tomatsu, Shunji and Pshezhetsky, Alexey V},
  title = {Heterologous HSPC Transplantation Rescues Neuroinflammation and Ameliorates Peripheral Manifestations in the Mouse Model of Lysosomal Transmembrane Enzyme Deficiency, MPS IIIC},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13100877}
}
Kostenlos starten →